Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMMU-130 · 1 trial · 1 indication
The primary outcome measured will be safety of IMMU-130 administered at different dose levels. Safety will be assessed by reviewing the number of adverse events and overall toxicity.
| Arm | Type | Description |
|---|---|---|
| IMMU-130 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| IMMU-130 | DRUG | IMMU-130 will be administered intravenously every 2 weeks for up to 6 months or longer. |
Inclusion Criteria: * Male or female patients, \>18 years of age, able to understand and give written informed consent. * Histologically or cytologically confirmed colorectal adenocarcinoma. * Stage IV (metastatic) disease. * Failed at least one prior standard treatment regimen for colorectal cance...
Top 20 of 77 competitors
IMMU-130 is an investigational small molecule being studied for the treatment of metastatic colorectal cancer. It is currently in Phase 1 clinical development and has not been approved by the FDA. A completed Phase 1 trial evaluated its use in patients with relapsed or refractory colorectal cancer.
IMMU-130 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with metastatic colorectal cancer.
IMMU-130 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. One Phase 1 trial has been completed, which enrolled 26 patients with metastatic colorectal cancer in the United States.
IMMU-130 has one completed clinical trial, identified as NCT01270698, titled 'Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer.' This Phase 1 trial enrolled 26 patients with metastatic colorectal cancer in the United States and has been completed.
No, IMMU-130 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for metastatic colorectal cancer. The drug has completed one Phase 1 trial, but it remains under investigation and has not been approved for any use.